布地奈德雾化吸入佐治小儿毛细支气管炎的疗效观察

来源 :实用心脑肺血管病杂志 | 被引量 : 0次 | 上传用户:lin0929
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
目的观察布地奈德(普米克令舒)雾化吸入佐治小儿毛细支气管炎的临床疗效及安全性。方法选择2012年12月—2014年3月我院收治的毛细支气管炎患儿124例,将其随机分为对照组和治疗组,各62例。对照组患儿采用常规综合对症治疗,治疗组患儿在常规综合对症治疗的基础上雾化吸入普米克令舒,均连续治疗1周。记录两组患儿临床症状消失时间,包括:咳嗽消失时间、喘憋消失时间及肺部啰音消失时间。观察两组患儿治疗效果及治疗期间不良反应情况。结果治疗组患儿咳嗽消失时间为(4.8±3.0)d、喘憋消失时间为(2.1±1.1)d、肺部啰音消失时间为(5.1±2.7)d,均短于对照组的(7.0±2.2)d、(3.3±1.4)d、(8.1±1.1)d(P<0.05)。治疗组患儿总有效率为93.5%,高于对照组的75.8%(P<0.05);治疗组患儿不良反应发生率为4.8%,低于对照组的8.1%(P<0.05)。结论普米克令舒雾化吸入佐治小儿毛细支气管炎具有显著的疗效,能够有效改善患儿临床症状,且操作简易,安全性高,值得临床推广使用。 Objective To observe the clinical efficacy and safety of budesonide (pulmicort) aerosol inhalation for children with bronchiolitis. Methods 124 patients with bronchiolitis admitted to our hospital from December 2012 to March 2014 were randomly divided into control group and treatment group, with 62 cases in each group. The control group of children with conventional comprehensive symptomatic treatment, treatment group children in the conventional comprehensive symptomatic treatment based on inhalation of pulmicort respules, were treated for 1 week. Record the disappearance of clinical symptoms in both groups, including the disappearance of cough, the disappearance of wheezing and the disappearance of pulmonary rales. The therapeutic effects of the two groups were observed and the adverse reactions during treatment were observed. Results The duration of cough disappearance in the treatment group was (4.8 ± 3.0) days, (2.1 ± 1.1) days in asthma disappearance and (5.1 ± 2.7) days in pulmonary rales, which were both shorter than those in control group (7.0 ± 2.2 d, 3.3 ± 1.4 d, 8.1 ± 1.1 d (P <0.05). The total effective rate in the treatment group was 93.5%, higher than that in the control group (75.8%, P <0.05). The incidence of adverse reactions in the treatment group was 4.8%, which was 8.1% less than that in the control group (P <0.05). Conclusion Pulmicort respiration inhalation of pediatric bronchiolitis has a significant effect, can effectively improve the clinical symptoms of children, and simple operation, high safety, it is worth promoting the use of the clinic.
其他文献
目前建议对1型糖尿病伴微量白蛋白尿患者,无论血压是否升高,均采用血管紧张素转化酶抑制剂(ACEI)治疗。作者对有关ACEI治疗1型糖尿病伴微量白蛋白尿的研究进行Meta分析,评价
传统的紫外线曝光难以制备微桥宽度不超过1微米的双晶约瑟夫森结.我们利用电子束曝光技术制备了纳米级别(几百纳米)桥宽YBa_2Cu_3O_(7-δ)双晶结,具有优良的电流-电压特性和
1过程工艺进展杭州林达公司具有自主知识产权的大甲醇技术已得到广泛应用。苏天化是我国现有几大甲醇厂之一,这套甲醇装置系引进日本三菱公司技术,日产甲醇600吨,原为冷激塔,
最近研究证实,微量白蛋白尿是糖尿病(DM)患者心血管事件另一个危险因素。据报道,中年Ⅰ型或Ⅱ型DM患者微量白蛋白尿发生率约30%,中年非DM者发生率约10%~15%。本文评价DM和非DM者
请下载后查看,本文暂不支持在线获取查看简介。 Please download to view, this article does not support online access to view profile.
旅游业是社会经济发达的产物 ,社会和人民财富的增加 ,意味着旅游事业大发展时机的到来 ,也意味着更高品质旅游时代的到来。十六大报告提出了全面建设小康社会的奋斗目标 ,这
讨论了网络环境下图书馆信息资源的构成及馆藏形式,图书馆信息资源的配置和共享。 Discussed in the network environment under the library information resources and th
本文对 44例甲状腺疾病患者血清甲状腺微粒体抗体(TMA)和甲状腺球蛋白抗体 (TGA)测定 ,现将结果报告如下。对象和方法一、对象 :(一 )正常人 :1 80例 (男 75 ,女 1 0 5) ,年龄 1 8~
目的:观察奥曲肽治疗小儿急性胰腺炎的临床效果。方法:选取于2010年3月-2014年9月期间在中山市博爱医院接受治疗的30例小儿急性胰腺炎患者,并根据治疗方式的不同将患者随机分
以4A-分子筛为载体,Dawson结构磷钨酸钇(Y_2P_2W_(18)O_(62)·nH_2O)为活性组分,采用浸渍法制备出负载型40%Y_2P_2W_(18)O_(62)·nH_2O/4A-分子筛,并通过FT IR、EDS、SEM、NH